1. Zhang S, Sun K, Zheng R, Zeng H, Wang S, Chen R, Wei W, He J: Cancer incidence and mortality in China, 2015. Journal of the National Cancer Center 2021, 1(1):2-11.
2. Lei S, Zheng R, Zhang S, Chen R, Wang S, Sun K, Zeng H, Wei W, He J: Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med 2021.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021, 71(3):209-249.
4. Burstein HJ, Griggs JJ, Prestrud AA, Temin S: American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract 2010, 6(5):243-246.
5. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC: Production and actions of estrogens. N Engl J Med 2002, 346(5):340-352.
6. Folkerd E, Dowsett M: Sex hormones and breast cancer risk and prognosis. Breast 2013, 22 Suppl 2:S38-43.
7. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE: Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995, 4(6):649-654.
8. Tamimi RM, Byrne C, Colditz GA, Hankinson SE: Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007, 99(15):1178-1187.
9. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE: Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006, 98(19):1406-1415.
10. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H et al: Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005, 97(10):755-765.
11. Key T, Appleby P, Barnes I, Reeves G, Endogenous H, Breast Cancer Collaborative G: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94(8):606-616.
12. Kensler KH, Eliassen AH, Rosner BA, Hankinson SE, Brown M, Tamimi RM: Pre-diagnostic sex hormone levels and survival among breast cancer patients. Breast Cancer Res Treat 2019, 174(3):749-758.
13. Duggan C, Stanczyk F, Campbell K, Neuhouser ML, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard R, McTiernan A: Associations of sex steroid hormones with mortality in women with breast cancer. Breast Cancer Res Treat 2016, 155(3):559-567.
14. Kim JY, Han W, Moon HG, Ahn SK, Kim J, Lee JW, Kim MK, Kim T, Noh DY: Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer 2013, 13:503.
15. Li J, Liu L, Feng Z, Wang X, Huang Y, Dai H, Zhang L, Song F, Wang D, Zhang P et al: Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer 2020, 27(4):621-630.
16. Zhang L, Huang Y, Feng Z, Wang X, Li H, Song F, Liu L, Li J, Zheng H, Wang P et al: Comparison of breast cancer risk factors among molecular subtypes: A case-only study. Cancer Med 2019, 8(4):1882-1892.
17. Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Mobus V, von Minckwitz G, Loibl S, Beckmann MW, Blohmer JU et al: 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). Breast Care (Basel) 2013, 8(3):221-229.
18. Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, Huang AJ, Vitolins M, Hubbell FA, Manson JE et al: Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 2011, 103(7):562-570.
19. Meira-Machado L, Cadarso-Suarez C, Gude F, Araujo A: smoothHR: an R package for pointwise nonparametric estimation of hazard ratio curves of continuous predictors. Comput Math Methods Med 2013, 2013:745742.
20. Harrell F: Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. New York City, NY: Springer; 2015.
21. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984, 2(10):1102-1109.
22. Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J: Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 2009, 117(1-3):31-41.
23. Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC: Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986, 22(4):515-525.
24. Bonney RC, Reed MJ, Davidson K, Beranek PA, James VH: The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clin Endocrinol (Oxf) 1983, 19(6):727-739.
25. Germain D: Estrogen carcinogenesis in breast cancer. Endocrinol Metab Clin North Am 2011, 40(3):473-484, vii.
26. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE: Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004, 96(24):1856-1865.
27. Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JA: Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1047-1051.
28. Micheli A, Meneghini E, Secreto G, Berrino F, Venturelli E, Cavalleri A, Camerini T, Di Mauro MG, Cavadini E, De Palo G et al: Plasma testosterone and prognosis of postmenopausal breast cancer patients. J Clin Oncol 2007, 25(19):2685-2690.
29. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S: Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006, 119(1):236-238.
30. Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, A'Hern R, Smith IE, Dowsett M: Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 2013, 138(1):157-165.
31. Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'Hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A et al: Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol 2010, 28(7):1161-1167.
32. Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, Jones LA, Caan BJ, Stefanick ML, Hajek RA et al: Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(3):614-620.
33. Lonning PE, Helle SI, Johannessen DC, Ekse D, Adlercreutz H: Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 1996, 39(3):335-341.
34. Folkerd EJ, Dowsett M: Influence of sex hormones on cancer progression. J Clin Oncol 2010, 28(26):4038-4044.